STELARA SQ®


 
 
 
 
 
 
 
 
 


 

STELARA SQ® (Ustekinumab) is an immunosuppressive drug that reduces inflammation in the body due to various autoimmune diseases.

STELARA SQ® is manufactured by Janssen Biotech.

Administration and Dosage:

For patients with Crohn’s disease, administration of STELARA is a regimen 1 intravenous infusion therapy followed by a maintenance dose of subcutaneous injections every 8 weeks. Patients with Plaque Psoriasis and Psoriatic Arthritis, STELARA is administred subcutaneously at week 1 and then week 4, followed by every 12 weeks regimen.

Common Side Effects:

The more common side effects of STELARA SQ® include serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

More Information:

Please read the full Prescribing Information and Medication Guide for STELARA SQ® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

STELARA SQ® is indicated to treat:

  • Crohn’s Disease
  • Plaque Psoriasis
  • Psoriatic Arthritis